Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases

ACS Medicinal Chemistry Letters

Volumn 2, Issue 8, 2011, Pages 559-564

  Hille, Ulrike E ^a   Zimmer, Christina ^a   Haupenthal, Jörg ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cushing's syndrome; CYP11B2; metabolic syndrome; selective inhibitors; steroid hormone biosynthesis; steroid 11 hydroxylase (CYP11B1)

Indexed keywords

ALDOSTERONE SYNTHASE; AROMATASE; CYTOCHROME; CYTOCHROME P450 11B1; CYTOCHROME P450 17; HYDROCORTISONE; IMIDAZOLYLMETHYLPYRIDINE; OXYGENASE INHIBITOR; PICOLINE DERIVATIVE; STEROID 11BETA MONOOXYGENASE; STEROID 11BETA MONOOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; NONHUMAN; PRIORITY JOURNAL;

EID: 80051710067     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100283h     Document Type: Article

References (31)

1. Diez, J. J.; Iglesias, P. Pharmacological therapy of Cushing's syndrome: Drugs and indications Mini-Rev. Med. Chem. 2007, 7, 467-480 (Pubitemid 46845794)
2. Engelhardt, D.; Weber, M. M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors J. Steroid Biochem. Mol. Biol. 1994, 49, 261-267 (Pubitemid 24240610)
3. Chu, J. W.; Matthias, D. F.; Joseph Belanoff, J.; Schatzberg, A.; Hoffman, A. R.; Feldman, D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486) J. Clin. Endocrinol. Metab. 2001, 86, 3568-3573 (Pubitemid 32755945)
4. Nieman, K. L. Medical therapy of Cushing's disease Pituitary 2002, 5, 77-82
5. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; Le Baut, G.; Hartmann, R. W.; Palzer, M. Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1 H -indoles and 3-(1-azoly1-1- phenylmethyl)-1 H -indoles as inhibitors of P450 arom Arch. Pharm. 1997, 330, 141-145 (Pubitemid 27298759)
6. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R. W.; Carotti, A. Design, synthesis and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 2004, 47, 6792-6803 (Pubitemid 40053767)
7. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 2006, 49, 4777-4780 (Pubitemid 44162705)
8. Dutta, U.; Pant, K. Aromatase inhibitors: past, present and future in breast cancer therapy Med. Oncol. 2008, 25, 113-124
9. Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17α-hydroxylase-C17,20-lyase(P450 17) Bioorg. Med. Chem. 2000, 8, 1245-1252 (Pubitemid 30398447)
10. Leroux, F.; Hutschenreuter, T.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. N -(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv. Chim. Act. 2003, 86, 2671-2686 (Pubitemid 37011982)
11. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme J. Enzyme Inhib. Med. Chem. 2004, 19, 17-32 (Pubitemid 38239927)
12. Attard, G.; Reid, A. H.; A'Hern, R.; Parker, C.; Oommen, N. B.; Folkerd, E.; Messiou, C.; Molife, L. R.; Maier, G.; Thompson, E.; Olmos, D.; Sinha, R.; Lee, G.; Dowsett, M.; Kaye, S. B.; Dearnaley, D.; Kheoh, T.; Molina, A.; de Bono, J. S. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 2009, 27, 3742-3748
13. Mornet, E.; Dupont, J.; Vitek, A.; White, P. C. Characterization of two genes encoding human steroid 11β-hydroxylase [P-450(11)β] J. Biol. Chem. 1989, 264, 20961-20967 (Pubitemid 20017902)
14. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
15. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 potency of pyridylnaphthalene type aldosterone synthase inhibitors: Influence of heteroaryl substitution on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
16. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis J. Med. Chem. 2005, 48, 6632-6642 (Pubitemid 41504720)
17. Ulmschneider, S.; Müller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Marchais-Oberwinkler, S.; Klein, C. D. P.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1796-1805 (Pubitemid 40396312)
18. Ulmschneider, S.; Müller-Vieira, U.; Klein, C. D. P.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase J. Med. Chem. 2005, 48, 1563-1575 (Pubitemid 40364563)
19. Ries, C.; Lucas, S.; Heim, R.; Birk, B.; Hartmann, R. W. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo J. Steroid Biochem. Mol. Biol. 2009, 116, 121-126
20. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: Lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin- 2-one derivates J. Med. Chem. 2008, 51, 8077-8087
21. Roumen, L.; Peeters, J. W.; Emmen, J. M. A.; Beugels, I. P. E.; Custers, E. M. G.; de Gooyer, M.; Plate, R.; Pieterse, K.; Hilbers, P. A. J.; Smits, J. F. M.; Vekemans, J. A. J.; Leysen, D.; Ottenheijm, H. C. J.; Janssen, H. M.; Hermans, J. J. R. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1 H -imidazoles as selective inhibitors of aldosterone synthase (CYP11B2) J. Med. Chem. 2010, 53, 1712-1725
22. Zolle, I. M.; Berger, M. L.; Hammerschmidt, F.; Hahner, S.; Schirbel, A.; Peric-Simov, B. New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues J. Med. Chem. 2008, 51, 2244-2253 (Pubitemid 351503279)
23. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases Med. Chem. Lett. 2011, 2, 2-6
24. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179 (Pubitemid 34876409)
25. Denner, K.; Doehmer, J.; Bernhardt, R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 chinese hamster cells Endocrine Res. 1995, 21, 443-448
26. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C(17,20)- lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63 (Pubitemid 32155424)
27. Hartmann, R. W.; Batzl, C. Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl) piperidine-2,6-diones J. Med. Chem. 1986, 29, 1362-1369 (Pubitemid 16034622)
28. Welles, B. Glucocorticoids in type 2 diabetes mellitus and the metabolic syndrome Drug Dev. Res. 2006, 67, 570-573 (Pubitemid 44851867)
29. Schwartz, S. L.; Rendell, M.; Ahmann, A. J.; Thomas, A.; Arauz-Pachecho, C. J.; Welles, B. R. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus Clin. Ther. 2008, 6, 1081-1088 (Pubitemid 351978117)
30. Arakaki, R.; Welles, B. Ketoconazole enantiomer for the treatment of diabetes mellitus Expert Opin. Investig. Drugs 2010, 19, 185-194
31. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010 (Pubitemid 351226569)